{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:51:34Z","timestamp":1792799494153,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"name":"Global Challenges Research Fund"},{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BVNCP-03"],"award-info":[{"award-number":["BVNCP-03"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2020.02.073","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T09:06:28Z","timestamp":1588064788000},"page":"4362-4373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3441","authenticated-orcid":false,"given":"Sami L.","family":"Gottlieb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ndowa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edward W.","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":false,"given":"Laith","family":"Abu-Raddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4817-8986","authenticated-orcid":false,"given":"Nicola","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6098-8610","authenticated-orcid":false,"given":"Helen","family":"Petousis-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-3528","authenticated-orcid":false,"given":"Kate L.","family":"Seib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2555-7756","authenticated-orcid":false,"given":"Birgitte K.","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2020.02.073_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2020.02.073_b0010","doi-asserted-by":"crossref","DOI":"10.1071\/SH19023","article-title":"World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2020.02.073_b0015","unstructured":"World Health Organization. Global health sector strategy on sexually transmitted infections, 2016\u20132021; 2016 [updated 2016\/07\/\/]. Available from: https:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/ghss-stis\/en\/."},{"key":"10.1016\/j.vaccine.2020.02.073_b0020","unstructured":"Wellcome Trust, Boston Consulting Group. Vaccines to tackle drug-resistant infections. An evaluation of R&D opportunities; 2016 [updated 2016]. Available from: https:\/\/vaccinesforamr.org\/read-the-report\/."},{"issue":"10102","key":"10.1016\/j.vaccine.2020.02.073_b0025","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.vaccine.2020.02.073_b0030","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"participants of the STI Vaccine Technical Consultation. Vaccines against sexually transmitted infections: the way forward","volume":"32","author":"Broutet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.073_b0035","doi-asserted-by":"crossref","DOI":"10.1071\/SH19060","article-title":"Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap","author":"Gottlieb","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2020.02.073_b0040","unstructured":"World Health Organization. WHO Preferred Product Characteristics (PPCs). Available from: http:\/\/www.who.int\/immunization\/research\/ppc-tpp\/preferred_product_characteristics\/en\/."},{"key":"10.1016\/j.vaccine.2020.02.073_b0045","doi-asserted-by":"crossref","DOI":"10.1071\/SH19061","article-title":"Epidemiology of gonorrhoea: a global perspective","author":"Kirkcaldy","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2020.02.073_b0050","series-title":"Sex Transm Dis","first-page":"627","article-title":"Gonococcal infections in the adult","author":"Hook","year":"2008"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.073_b0055","doi-asserted-by":"crossref","first-page":"e1002511","DOI":"10.1371\/journal.pmed.1002511","article-title":"Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies","volume":"15","author":"Torrone","year":"2018","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.073_b0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12879-018-3003-2","article-title":"Concordance of gonorrhoea of the rectum, pharynx and urethra in same-sex male partnerships attending a sexual health service in Melbourne, Australia","volume":"18","author":"Cornelisse","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"21","key":"10.1016\/j.vaccine.2020.02.073_b0065","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra1411426","article-title":"Pelvic inflammatory disease","volume":"372","author":"Brunham","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.02.073_b0070","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1086\/652395","article-title":"Risk of sequelae after Chlamydia trachomatis genital infection in women","volume":"201","author":"Haggerty","year":"2010","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2020.02.073_b0075","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/ciz145","article-title":"Risk of ectopic pregnancy and tubal infertility following gonorrhea and chlamydia infections","volume":"69","author":"Reekie","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.073_b0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00007435-199207000-00001","article-title":"Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results","volume":"19","author":"Westrom","year":"1992","journal-title":"Sex TransmDis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.073_b0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/AOG.0b013e31825a6bc9","article-title":"Subclinical pelvic inflammatory disease and infertility","volume":"120","author":"Wiesenfeld","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.073_b0090","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0002-9378(11)90790-X","article-title":"Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility","volume":"168","author":"Hillis","year":"1993","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.073_b0095","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/OLQ.0000000000000592","article-title":"Adverse birth outcomes and maternal Neisseria gonorrhoeae infection: A population-based cohort study in Washington State","volume":"44","author":"Heumann","year":"2017","journal-title":"Sex Transm Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.073_b0100","first-page":"471","article-title":"Epidemiology and control of gonococcal ophthalmia neonatorum","volume":"67","author":"Laga","year":"1989","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2020.02.073_b0105","unstructured":"World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae; 2016 [updated 2016]. Available from: https:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/gonorrhoea-treatment-guidelines\/en\/."},{"issue":"Suppl 6","key":"10.1016\/j.vaccine.2020.02.073_b0110","article-title":"Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy","volume":"22","author":"Cohen","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2020.02.073_b0115","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.aids.0000390704.35642.47","article-title":"Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?","volume":"24","author":"Hayes","year":"2010","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.vaccine.2020.02.073_b0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/01.olq.0000154504.54686.d1","article-title":"Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection","volume":"32","author":"Sexton","year":"2005","journal-title":"Sex Transm Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.02.073_b0125","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/OLQ.0b013e3181812d15","article-title":"The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis","volume":"35","author":"Johnson","year":"2008","journal-title":"Sex Transm Dis"},{"issue":"9907","key":"10.1016\/j.vaccine.2020.02.073_b0130","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(13)61947-9","article-title":"Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)","volume":"382","author":"Sonnenberg","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2020.02.073_b0135","doi-asserted-by":"crossref","first-page":"e0205863","DOI":"10.1371\/journal.pone.0205863","article-title":"Adult gonorrhea, chlamydia and syphilis prevalence, incidence, treatment and syndromic case reporting in South Africa: Estimates using the Spectrum-STI model, 1990\u20132017","volume":"13","author":"Kularatne","year":"2018","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.073_b0140","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1071\/SH15227","article-title":"Prevalence and risk factors of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and other sexually transmissible infections among women attending antenatal clinics in three provinces in Papua New Guinea: a cross-sectional survey","volume":"13","author":"Vallely","year":"2016","journal-title":"Sex Health"},{"issue":"12","key":"10.1016\/j.vaccine.2020.02.073_b0145","doi-asserted-by":"crossref","first-page":"e0208107","DOI":"10.1371\/journal.pone.0208107","article-title":"Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection - A meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis","volume":"13","author":"Werner","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.02.073_b0150","unstructured":"The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2018 | UNSW - The Kirby Institute for infection and immunity in society; 2018."},{"key":"10.1016\/j.vaccine.2020.02.073_b0155","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018; 2019 [updated 2019\/08\/27\/]. Available from: https:\/\/www.cdc.gov\/std\/stats18\/default.htm."},{"key":"10.1016\/j.vaccine.2020.02.073_b0160","unstructured":"Public Health England. Sexually transmitted infections and screening for chlamydia in England, 2018; 2019 [updated 2019]. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/806118\/hpr1919_stis-ncsp_ann18.pdf."},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.073_b0165","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"8455","key":"10.1016\/j.vaccine.2020.02.073_b0170","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0140-6736(85)90594-X","article-title":"Worldwide patterns of infertility: is Africa different?","volume":"2","author":"Cates","year":"1985","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.073_b0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.073_b0180","doi-asserted-by":"crossref","first-page":"e1002344-e","DOI":"10.1371\/journal.pmed.1002344","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action","volume":"14","author":"Wi","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2020.02.073_b0185","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2017 [updated 2017\/02\/27\/]. Available from: https:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic-resistant-bacteria\/en\/."},{"key":"10.1016\/j.vaccine.2020.02.073_b0190","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12879-015-1029-2","article-title":"Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge","volume":"15","author":"Unemo","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"25","key":"10.1016\/j.vaccine.2020.02.073_b0195","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1512757","article-title":"Failure of dual antimicrobial therapy in treatment of gonorrhea","volume":"374","author":"Fifer","year":"2016","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.vaccine.2020.02.073_b0200","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"issue":"12","key":"10.1016\/j.vaccine.2020.02.073_b0205","doi-asserted-by":"crossref","first-page":"e018630","DOI":"10.1136\/bmjopen-2017-018630","volume":"7","author":"Vallely","year":"2017","journal-title":"BMJ Open"},{"issue":"Suppl 6","key":"10.1016\/j.vaccine.2020.02.073_b0210","doi-asserted-by":"crossref","first-page":"e25343","DOI":"10.1002\/jia2.25343","article-title":"Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward","volume":"22","author":"Wi","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.073_b0215","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/sextrans-2017-053273","article-title":"100 years of STIs in the UK: a review of national surveillance data","volume":"94","author":"Mohammed","year":"2018","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2020.02.073_b0220","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-micro-090816-093530","article-title":"Neisseria gonorrhoeae: Drug resistance, mouse models, and vaccine development","volume":"71","author":"Rice","year":"2017","journal-title":"Annu Rev Microbiol"},{"issue":"2417","key":"10.1016\/j.vaccine.2020.02.073_b0225","first-page":"1","article-title":"Progress toward a gonococcal vaccine: The way forward","volume":"10","author":"Russell","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.073_b0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/oxfordjournals.aje.a009820","article-title":"Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae","volume":"149","author":"Fox","year":"1999","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.02.073_b0235","doi-asserted-by":"crossref","DOI":"10.1099\/mgen.0.000239","article-title":"Using genomics to understand antimicrobial resistance and transmission in Neisseria gonorrhoeae","author":"S\u00e1nchez-Bus\u00f3","year":"2019","journal-title":"Microb Genom"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.073_b0240","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/mi.2012.12","article-title":"Neisseria gonorrhoeae selectively suppresses the development of Th1 and Th2 cells, and enhances Th17 cell responses, through TGF-\u03b2-dependent mechanisms","volume":"5","author":"Liu","year":"2012","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.073_b0245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/infdis\/jiv024","article-title":"Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model","volume":"212","author":"Gulati","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.073_b0250","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: A Retrospective Cohort Study","volume":"7","author":"Paynter","year":"2019","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"10.1016\/j.vaccine.2020.02.073_b0255","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.073_b0260","first-page":"53","article-title":"Mucosal approaches in Neisseria vaccinology","volume":"18","author":"P\u00e9rez","year":"2009","journal-title":"VacciMonitor"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.073_b0265","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/infdis\/jiy609","article-title":"A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor H binding protein elicits gonococcal bactericidal antibodies","volume":"219","author":"Beernink","year":"2019","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.073_b0270","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cid\/ciy1061","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","volume":"69","author":"Semchenko","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.073_b0275","unstructured":"Connolly KL, Leduc I, Rahman N, Sempowski G, Jerse AE. The group B meningococcal vaccine Bexsero induces antibodies that recognize several candidate gonorrhea vaccine targets and shows protective efficacy against experimental Neisseria gonorrhoeae genital tract infection in mice. In Proceedings of the 21st International Pathogenic Neisseria Conference; 23\u201328 September 2018; Pacific Grove, CA, USA; 2018."},{"key":"10.1016\/j.vaccine.2020.02.073_b0280","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1016\/j.vaccine.2018.02.081","article-title":"Biological feasibility and importance of a gonorrhea vaccine for global public health","volume":"37","author":"Vincent","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.073_b0285","article-title":"Novel whole-cell inactivated Neisseria gonorrhoeae microparticles as vaccine formulation in microneedle-based transdermal immunization","volume":"6","author":"Gala","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2020.02.073_b0290","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2011.00123","article-title":"Experimental gonococcal infection in male volunteers: Cumulative experience with Neisseria gonorrhoeae strains FA1090 and MS11mkC","volume":"2","author":"Hobbs","year":"2011","journal-title":"Front Microbiol"},{"issue":"14","key":"10.1016\/j.vaccine.2020.02.073_b0295","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.vaccine.2013.08.032","article-title":"Current barriers, challenges and opportunities for the development of effective STI vaccines: point of view of vaccine producers, biotech companies and funding agencies","volume":"32","author":"Dodet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.073_b0300","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1016\/j.vaccine.2017.03.074","article-title":"Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling","volume":"37","author":"Gottlieb","year":"2019","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.vaccine.2020.02.073_b0305","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1016\/j.vaccine.2015.07.015","article-title":"The potential impact of vaccination on the prevalence of gonorrhea","volume":"33","author":"Craig","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.02.073_b0310","first-page":"A232","article-title":"The impact of gonorrhoea vaccination in men who have sex with men on prevalence and resistance: Mathematical modelling study","volume":"95","author":"Heijne","year":"2019","journal-title":"Sex Transm Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2020.02.073_b0315","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.4161\/hv.36221","article-title":"Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model","volume":"10","author":"R\u00e9gnier","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.073_b0320","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00007435-197804000-00003","article-title":"Dynamics and control of the transmission of gonorrhea","volume":"5","author":"Yorke","year":"1978","journal-title":"Sex Transm Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2020.02.073_b0325","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.vaccine.2013.11.007","article-title":"The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease","volume":"32","author":"Garnett","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.073_b0330","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/OLQ.0b013e318285c6d2","article-title":"The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008","volume":"40","author":"Owusu-Edusei","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.073_b0335","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/OLQ.0000000000000725","article-title":"An illustration of the potential health and economic benefits of combating antibiotic-resistant gonorrhea","volume":"45","author":"Chesson","year":"2018","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.073_b0340","doi-asserted-by":"crossref","first-page":"e0170773","DOI":"10.1371\/journal.pone.0170773","article-title":"Costing of national STI program implementation for the Global STI Control Strategy for the Health Sector, 2016\u20132021","volume":"12","author":"Korenromp","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.02.073_b0345","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013; 2013. Available from: https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf."},{"key":"10.1016\/j.vaccine.2020.02.073_b0350","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiz153","article-title":"Population-level antimicrobial consumption is associated with decreased antimicrobial susceptibility in Neisseria gonorrhoeae in 24 European countries: an ecological analysis","author":"Kenyon","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.073_b0355","unstructured":"World Health Organization. Value attribution framework for vaccines against antimicrobial resistance; 2019. Available from: https:\/\/www.who.int\/immunization\/research\/meetings_workshops\/5_Hasso_Prudden_AMR_PDVAC_2019.pdf?ua=1."},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.073_b0360","doi-asserted-by":"crossref","first-page":"e1002366","DOI":"10.1371\/journal.pmed.1002366","article-title":"Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines","volume":"14","author":"Alirol","year":"2017","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.073_b0365","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12879-017-2541-3","article-title":"A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol","volume":"17","author":"Chow","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"43","key":"10.1016\/j.vaccine.2020.02.073_b0370","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations","volume":"35","author":"World Health Organization","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.073_b0375","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/OLQ.0b013e318244a923","article-title":"Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics","volume":"39","author":"Hoover","year":"2012","journal-title":"Sex Transm Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.073_b0380","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/21645515.2018.1458175","article-title":"Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines","volume":"14","author":"Villena","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"26","key":"10.1016\/j.vaccine.2020.02.073_b0385","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2016.03.111","article-title":"The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps","volume":"34","author":"Gottlieb","year":"2016","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.02.073_b0390","first-page":"B5","article-title":"Decade of vaccine collaboration","volume":"31","author":"Global Vaccine Action Plan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.073_b0395","unstructured":"World Health Organization. Global Vaccine Action Plan 2011\u20132020; 2012 [updated 2012]. Available from: http:\/\/www.who.int\/immunization\/global_vaccine_action_plan\/GVAP_doc_2011_2020\/en\/."},{"key":"10.1016\/j.vaccine.2020.02.073_b0400","unstructured":"Every Woman Every Child. Global Strategy for Women's, Children's and Adolescents Health 2016\u20132030; 2015 [updated 2015]. Available from: https:\/\/www.who.int\/life-course\/publications\/global-strategy-2016-2030\/en\/."},{"key":"10.1016\/j.vaccine.2020.02.073_b0405","unstructured":"World Health Organization. Global action plan on antimicrobial resistance; 2015 [updated 2015]. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/193736\/9789241509763_eng.pdf;jsessionid=96D175C723729F840B5C008ADBD609B7?sequence=1."},{"key":"10.1016\/j.vaccine.2020.02.073_b0410","unstructured":"World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Available from: https:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/9789241503501\/en\/."},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.073_b0415","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/CVI.00230-16","article-title":"Summary and recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) workshop \u201cGonorrhea Vaccines: the Way Forward\u201d","volume":"23","author":"Wetzler","year":"2016","journal-title":"Clin Vacc Immunol"},{"issue":"S4","key":"10.1016\/j.vaccine.2020.02.073_b0420","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1136\/sextrans-2016-053071","article-title":"Advancing prevention of sexually transmitted infections through point-of-care testing: target product profiles and landscape analysis","volume":"93","author":"Toskin","year":"2017","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2020.02.073_b0425","unstructured":"World Health Organization. Standard protocol to assess prevalence of gonorrhoea and chlamydia among pregnant women in antenatal care clinics; 2018 [updated 2018]. Available from: http:\/\/www.who.int\/reproductivehealth\/publications\/rtis\/gonorrhoea-chlamydia-among-pregnant-women\/en\/"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.073_b0430","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/OLQ.0b013e318151497d","article-title":"The natural history of untreated Chlamydia trachomatis infection in the interval between screening and returning for treatment","volume":"35","author":"Geisler","year":"2008","journal-title":"Sex Transm Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2020.02.073_b0435","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/infdis\/jit094","article-title":"Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection","volume":"207","author":"Geisler","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.073_b0440","article-title":"Disseminated gonococcal infections in patients receiving eculizumab: a case series","author":"Crew","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:44:28Z","timestamp":1759401868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20303170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":88,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X20303170"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 World Health Organization; licensee Elsevier.","name":"copyright","label":"Copyright"}]}}